Assembly Biosciences (ASMB) Cash from Financing Activities (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly Cash from Financing Activities of $149000.0 for Q1 2026, down 92.25% year-over-year from $1.9 million in Q1 2025, and down 67.32% quarter-over-quarter from $456000.0 in Q4 2025.
Assembly Biosciences (ASMB) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Assembly Biosciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $149000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 92.25% year-over-year to $149000.0; the TTM figure through Mar 2026 stood at $172.9 million (up 451.13% YoY), while the FY2025 annual figure was $174.7 million, up 493.12% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $149000.0, down from $456000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $171.9 million in Q3 2025, with the low at $134000.0 in Q2 2023.
- The 5-year median for Cash from Financing Activities is $1.2 million (2025), against an average of $18.2 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 9194.03% in 2024, then slumped 97.32% in 2025.
- Assembly Biosciences' Cash from Financing Activities stood at $437000.0 in 2022, then soared by 2003.43% to $9.2 million in 2023, then soared by 84.89% to $17.0 million in 2024, then plunged by 97.32% to $456000.0 in 2025, then sank by 67.32% to $149000.0 in 2026.
- Business Quant data shows ASMB's Cash from Financing Activities at $149000.0 in Q1 2026, $456000.0 in Q4 2025, and $171.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 108.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.74 Mn |
| Jun 30, 2026 | 108.74 Mn |
| Mar 31, 2026 | 149,000.00 |
| Mar 31, 2026 | 149,000.00 |
| Dec 31, 2025 | 456,000.00 |
| Dec 31, 2025 | 456,000.00 |
| Sep 30, 2025 | 171.93 Mn |
| Sep 30, 2025 | 171.93 Mn |
| Jun 30, 2025 | 357,000.00 |
| Jun 30, 2025 | 357,000.00 |
| Mar 31, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 17.00 Mn |
| Dec 31, 2024 | 17.00 Mn |
| Jun 30, 2024 | 12.45 Mn |
| Jun 30, 2024 | 12.45 Mn |
| Dec 31, 2023 | 9.19 Mn |
| Dec 31, 2023 | 9.19 Mn |
| Jun 30, 2023 | 134,000.00 |
| Jun 30, 2023 | 134,000.00 |